Clinical trials: Cannabis
Healthy Adult Participants
Evaluation of BRC-002 Safety, Tolerability, Pharmacokinetics, and Food Effects in Healthy Participants
This study will evaluate the safety and tolerability of BRC-002, an investigational botanical drug from cannabis, in healthy adults.
- Trial name
- NCT07699120
- Testing
- BRC-002
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Biopharmaceutical Research Company
Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis
Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.
This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses. This study will be conducted in two parts: Phase I single ascending dose (SAD) and Phase Ib multiple…
- Trial name
- NCT06038279
- Testing
- INI-2004
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Inimmune Corporation
Hepatic Impairment
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
A Phase I open-label study to evaluate the pharmacokinetics (what the body does to a drug), safety and tolerability of a single dose of Sativex (containing 10.8 mg tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) in…
- Trial name
- NCT01887301
- Testing
- Sativex
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Healthy
A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract
This study is an open-label, single-dose, healthy volunteer phase 1 study after overnight fasting designed to study the safety and PK of medicated drops and tablet formulation for sublingual administration.
- Trial name
- NCT04261166
- Testing
- A1, A2, A3
- Where
- Israel
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Breath of Life International Pharma Ltd
Acute Cannabinoid Intoxication
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test
The aim of this study is to investigate whether ANEB-001 effectively penetrates the brain and inhibits the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis.
- Trial name
- NCT05282797
- Testing
- ANEB-001
- Where
- Netherlands
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Anebulo Pharmaceuticals
Evaluation of Abuse Potential of Sativex
Abuse Potential of Sativex
This crossover study with six treatment sessions is to evaluate the abuse potential of three doses of Sativex as compared to Marinol and placebo, in subjects with a history of recreational marijuana use.
- Trial name
- NCT01323569
- Testing
- Sativex, Marinol
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Autistic Disorder
A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
This single center, double-blinded, randomized, placebo-controlled crossover trial will assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30% CBD and 1.5% Δ9-THC) vs.
- Trial name
- NCT05413187
- Testing
- Medical Grade Cannabis oil
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- TO Pharmaceuticals
Food Effect
Study to Assess Food Effect on Sativex Bioavailability
Study to assess effect of food on the bioavailability of a single dose of Sativex and to measure its' pharmacokinetics after a single and multiple doses.
- Trial name
- NCT01322464
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Cannabis Intoxication
Cannabis Impairment Detection Device Study
The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question[s] it aims to answer are: Is the investigational device accurate and reliable at detecting cannabis…
- Trial name
- NCT07122349
- Testing
- Cannabis Impairment Test
- Where
- Canada
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Gaize
Driving Under the Influence, Marijuana Intoxication
Cannabis Impairment Detection Application (CIDA)
Subjects will participate in a 4-visit study protocol in which they will be asked to complete a set of computerized tasks and a 45-minute simulated drive in a driving simulator.
- Conditions
- Driving Under the Influence, Marijuana Intoxication, Alcohol Intoxication
- Trial name
- CIDA (NCT04230460)
- Testing
- Cannabis (High% THC) (Inhaled), Cannabis (Very High% THC) (Inhaled), Alcohol (oral)
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Advanced Brain Monitoring, Inc.
Healthy
Single and Multiple Dose Study of VER-01 in Healthy Volunteers
Evaluation of pharmacokinetics, tolerability and safety of VER-01 in healthy volunteers
- Trial name
- NCT04930809
- Testing
- VER-01
- Where
- Austria
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Vertanical GmbH
Healthy Volunteers
A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects
To evaluate the effect of oral pH on the pharmacokinetics (PK) of a single oromucosal dose of Sativex (four sprays containing 10.8 mg Δ9 tetrahydrocannabinol (THC) and 10 mg cannabidiol (CBD)) by comparing the PK profile of…
- Trial name
- NCT02240160
- Testing
- Sativex
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GW Pharmaceuticals Ltd
Healthy
Safety and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare
The goal of this Phase I clinical trial is to assess the pharmacokinetic availability and safety and tolerability profile of Extrato de Cannabis sativa GreenCare 79.14 mg/mL.
- Trial name
- NCT06807762
- Testing
- Cannabis oil
- Where
- Brazil
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GreenCare Pharma
Smoking Cessation, Marijuana Use
Project CheckUP: A Brief Behavioral Intervention for Quitline Callers Who Use Marijuana (MJ) and Tobacco
Smoking cigarettes remains the number one preventable cause of death and disease in the US. Smokers who call tobacco quitlines and use marijuana struggle to quit tobacco due to the interactive effects of nicotine and marijuana.
- Trial name
- NCT04737772
- Testing
- Behavioral: Quitline treatment as usual, QL Marijuana Check-Up intervention (QL-MJCU)
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Pharmacokinetic, Tolerability
Clinical Trial on Pharmacokinetic and Tolerability of AP701
This study aims to investigate the uptake of AP701, a preparation from cannabis flowers, into the bloodstream after in single administration in healthy volunteers.
- Conditions
- Pharmacokinetic, Tolerability, Safety
- Trial name
- NCT04708795
- Testing
- AP701
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- CannaXan GmbH
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.
- Conditions
- Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
- Trial name
- NCT01323465
- Testing
- Sativex and rifampicin, Sativex and ketoconazole, Sativex and omeprazole
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Healthy Volunteers
5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers
The primary objective of the study was to evaluate the safety and tolerability of novel oral capsules containing THC and/or CBD, following a single administration to healthy volunteers.
- Trial name
- NCT03201835
- Testing
- PNL-THC:CBD soft gelatin capsule, Sativex, CBD hard capsule dose 1
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- PhytoTech Therapeutics, Ltd.
Effects of Sativex on ECG
Sativex Thorough QT/QTc Study
This study was to evaluate effects of Sativex on electrocardiogram (ECG) traces when administered at its therapeutic dose of 8 sprays per day and at multiples of the therapeutic dose (24 or 36 sprays per day), and to evaluate its…
- Trial name
- NCT01322139
- Where
- Canada
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Health, Subjective, Inflammatory Response
Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over.
- Conditions
- Health, Subjective, Inflammatory Response, Adverse Effect, Side Effect
- Trial name
- NCT05743985
- Testing
- Cannabigerol
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Formula30A LLC
Healthy Volunteers
Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients
No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis.
- Trial name
- NCT04314804
- Testing
- PPP001
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tetra Bio-Pharma